Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469588 | 0.87 | ACACB (0.30) | ACACB | |
| SCHEMBL15469594 | 0.87 | PDGFRB (0.34) | ACACBALDH1A1F2GLAHPGD | |
| SCHEMBL15469614 | 0.86 | IMPDH2 (0.33) | ALDH1A1F2GLAHPGD | |
| SCHEMBL533268 | 0.86 | MET (0.33) | METALDH1A1F2GLAHPGD | |
| SCHEMBL632771 | 0.85 | HPGDS (0.36) | METALDH1A1F2GLAHPGD | |
| SCHEMBL2865535 | 0.84 | ALDH1A1 (0.35) | METALDH1A1F2GLAHPGD | |
| SCHEMBL15469578 | 0.84 | MET (0.31) | METALDH1A1F2GLAHPGD | |
| SCHEMBL632862 | 0.84 | ALDH1A1 (0.33) | METALDH1A1F2GLAHPGD | |
| SCHEMBL3732272 | 0.84 | MEN1 (0.36) | METALDH1A1F2GLAHPGD | |
| SCHEMBL15469632 | 0.83 | ALDH1A1 (0.31) | METALDH1A1F2GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045890-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045890-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045890-A1 | NOVEL COMPOUNDS | CYP1B1, CYP1A1, CYP51A1 | ACACB 2332/4885MET 3339/4885ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.